Cardiovascular and renal outcomes, and mortality in Danish patients with type 2 diabetes who initiate empagliflozin versus GLP1-RA: A Danish nationwide comparative effectiveness study (EMPLACE) First published 04/06/2019 Last updated 02/04/2024 EU PAS number:EUPAS29985 Study Ongoing